BioSpace News Archive

Evozyne, LLC, a privately held molecular engineering technology company founded by life science innovator Paragon Biosciences, announced today the signing of a strategic collaboration with a leading company in rare disorders for the development and commercialization of novel biopharmaceuticals for immune modulation.

Galderma announces that the U.S. Food and Drug Administration (FDA) has approved Restylane ® Defyne for the augmentation and correction of mild to moderate chin retrusion for adults

FEops, a digital health leader in personalized predictive planning for structural heart interventions, is proud to announce having modeled 2000 patients with FEops HEARTguide™ for the pre-operative planning of structural heart interventions.

The financing will be used to advance its AI-guided laser platform to automate and scale autologous cell-and tissue-based therapies.

NTT Research, Inc., a division of NTT (TYO:9432), today announced that it has named Dr. Jon Nels Peterson a Senior Scientist in its Medical & Health Informatics (MEI) Lab.

- Exelixis will utilize Adagene’s proprietary SAFEbody ™ technology to develop novel masked antibody-drug conjugates (ADCs) with potential for improved therapeutic index -

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), today announced that it has entered into a settlement agreement with Zydus Worldwide DMCC and Zydus Pharmaceuticals (USA) Inc. (“Zydus”) resolving its ongoing litigation concerning Zydus’s Abbreviated New Drug Application (“ANDA”) seeking approval by the U.S. Food and Drug Administration to market a generic version of GOCOVR

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that early onset of action data for Qtrypta™, Zosano’s investigational therapy for the acute treatment of migraine formulated utilizing its microneedle system, were presented at the Annual Headache Cooperative of the Pacific Winter Conference

Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced significant progress in its role as Data Coordinating Center for studies conducted under the Best Pharmaceuticals for Children Act (BPCA).

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its first quarter fiscal 2021 conference call on Tuesday, February 9, at 7:30 a.m. CT (8:30 a.m. ET).